Module 2: Approved Immune Checkpoint Inhibitors and Antibody-Drug Conjugate Combinations in First-Line a/mUC

Primary Audience:

This activity is intended to meet the educational needs of oncologists and oncology advanced practice providers involved in the care of patients with advanced and metastatic urothelial carcinoma.

This module will cover the recent evidence for approved treatments of cisplatin-ineligible/platinum-ineligible advanced/metastatic UC (a/mUC), with an emphasis on immune checkpoint inhibitors (ICIs) and antibody-drug conjugate (ADC) combinations.

Max Kates, MD

Max Kates, MD
Director, Bladder Cancer Program
Associate Professor of Urology
Associate Professor of Oncology
Johns Hopkins Greenburg Bladder Cancer Institute
Baltimore, MD

Dr. Max Kates is an Associate Professor of Urology and Oncology in the Brady Urological Institute. He also directs the Division of Urologic Oncology for the Brady Urological Institute.

Dr. Kates received his undergraduate degree from Wesleyan University in Connecticut, and his medical degree from Mount Sinai School of Medicine in New York. During that time he completed a Doris Duke clinical research fellowship in Urologic Oncology at Columbia University, College of Physicians and Surgeons.

Dr. Kates has expertise in all areas of urologic oncology, including prostate, bladder, kidney, testicular, and genital cancers. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. 

As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches.

Dr. Kates’ research interest parallel his clinical practice, with an emphasis on novel treatments for cancers of the urinary tract. He has a particular interest in developing novel therapies for bladder cancer, and currently has a provisional patent for a novel intravesical chemotherapy he developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer.

Dr. Kates has authored more than 70 journal articles in the fields of bladder, prostate, and kidney cancer. He has won numerous awards, including the American Urologic Association (AUA) Russell Scott Award, best poster awards from the society of urologic oncology and AUA, and best reviewer from the journal Urologic Oncology. 

Apply an understanding of the mechanisms, indications, and safety profiles of IO therapies and ADCs in the treatment of a/mUC.